16 completed, 3 terminated, 1 withdrawn. 12 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Terminated 2, Withdrawn 1 |
| Phase 1 | 11 | Completed 9, Terminated 2 |
Follow sotrastaurin: new trials by email Literature Review of sotrastaurin trials Research Report on sotrastaurin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation sotrastaurin acetate, pharmacological study, laboratory biomarker analysis - Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma | Phase 2 | Withdrawn | James Blachly | 2015-03-12 | 2017-04-05 | |
| Trial of AEB071 in Combination With BYL719 in Patients With Melanoma AEB071, BYL719 - Uveal Melanoma | Phase 1 | Completed | Columbia University | 30 | 2014-11-19 | 2023-08-15 |
| Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma AEB071, Everolimus - CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Novartis Pharmaceuticals | 31 | 2013-12-05 | 2020-12-19 |
| A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma AEB071, MEK162 - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Array Biopharma, now a wholly owned subsidiary of Pfizer | 38 | 2013-08-01 | 2020-09-16 |
| Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients AEB071 - Uveal Melanoma | Phase 1 | Completed | Novartis Pharmaceuticals | 153 | 2011-12-20 | 2020-12-19 |
| Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma AEB071 - Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 15 | 2011-11-01 | 2020-12-19 |
| Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis AEB071, Placebo - Ulcerative Colitis | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2010-04-01 | 2020-12-22 |
| Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications - Liver Transplantation | Phase 2 | Completed | Novartis Pharmaceuticals | 200 | 2010-04-01 | 2020-12-22 |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications - Renal Transplantation | Phase 2 | Completed | Novartis Pharmaceuticals | 298 | 2009-12-01 | 2020-12-22 |
| CAEB071 Thorough QTc Study in Healthy Volunteers sotrastaurin, placebo to sotrastaurin, Avelox - Healthy | Phase 1 | Completed | Novartis Pharmaceuticals | 100 | 2009-07-01 | 2012-05-09 |
| A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis Placebo, AEB071 - Moderate and Severe Plaque Psoriasis | Phase 2 | Completed | Novartis Pharmaceuticals | 336 | 2009-04-01 | 2020-12-22 |
| Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients cyclosporine (reduced exposure) / everolimus, AEB071 300 mg b.i.d. / everolimus, AEB071 200 mg b.i.d. / everolimus - Kidney Transplantation | Phase 2 | Completed | Novartis Pharmaceuticals | 175 | 2008-09-01 | 2017-02-24 |
| Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis AEB071 - Uveitis, Posterior Uveitis | Phase 2 | Completed | Novartis | 13 | 2008-07-01 | 2020-12-22 |
| Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation AEB071 - de Novo Liver Transplantation | Phase 1 | Completed | Novartis | 13 | 2007-10-01 | 2020-12-08 |
| 24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients AEB071, mycophenolic plus tacrolimus - Kidney Transplantation | Phase 2 | Terminated | Novartis Pharmaceuticals | 137 | 2007-10-01 | 2020-12-17 |
| Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients AEB071, Certican, Neoral - Kidney Transplantation | Phase 2 | Completed | Novartis Pharmaceuticals | 311 | 2007-07-01 | 2016-11-18 |
| Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation AEB071 - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 124 | 2007-01-01 | 2020-12-22 |
| Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects AEB071 - Healthy | Phase 1 | Completed | Novartis | 96 | 2006-10-01 | 2008-08-11 |
| Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients AEB071, Mycophenolic Acid - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 215 | 2006-10-01 | 2020-12-17 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071 AEB071 - Healthy | Phase 1 | Completed | Novartis | 16 | 2006-06-01 | 2010-10-19 |
Rejection, Psychology (3) · Uveal Melanoma (3) · Lymphoma, Large B-Cell, Diffuse (2) · Melanoma (2) · Colitis, Ulcerative (1) · Dermatitis (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Macular Edema (1) · Neoplasm Metastasis (1) · Panuveitis (1) · Psoriasis (1) · Uveitis (1)
Novartis Pharmaceuticals (13) · Novartis (4) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Columbia University (1) · James Blachly (1)
United States (14) · Germany (13) · France (9) · Italy (9) · Spain (8) · United Kingdom (8) · Netherlands (7) · Switzerland (7) · Belgium (6) · Canada (6) · Argentina (5) · Australia (4) · Taiwan (4) · Austria (3) · Brazil (3)
James Blachly, MD (1) · Richard Carvajal, MD (1)
PMID 21564523, PMID 23659755, PMID 23668931, PMID 25677074
2008 (1), 2009 (1)